Myungin Pharm명인제약
317450 · KOSPI · ₩317450 · 명인제약
₩40,200▲ ₩300 (0.75%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | |
|---|---|
| Revenue | ₩287B |
| Cost of sales | ₩113B |
| Gross profit | ₩174B |
| Operating income | ₩92B |
| Net income | ₩81B |
| Net income to shareholders | ₩81B |
Balance sheet
| 2025 | |
|---|---|
| Total assets | ₩842B |
| Current assets | ₩643B |
| Cash and equivalents | ₩32B |
| Total liabilities | ₩47B |
| Current liabilities | ₩46B |
| Total equity | ₩794B |
| Shareholders' equity | ₩794B |
Cash flow
| 2025 | |
|---|---|
| Cash from operations | ₩82B |
| Capital spending | ₩30B |
| Free cash flow | ₩52B |
| Dividends paid | ₩11B |
Consolidated where available. Amounts in won.
Also known as: Myungin Pharm / 명인제약 / 317450 / KRX:317450
Source: KRX statistical information